BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PALO ALTO, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #biomanufacturing--BridgeBio Pharma, Inc. (NASDAQ: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced a strategic collaboration to manufacture and advance BBP-812, an investigational adeno-associated virus (AAV) 9 gene therapy for Canavan disease, and BBP-6.

BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments

BridgeBio Pharma's Q2 2023 YoY revenue plummeted, but PIPE financing extends cash runway to 15 months, alleviating short-term liquidity concerns. Acoramidis poses a threat to Pfizer's tafamidis in ATTR-CM space, pending FDA approval; yet high debt and complex capital structure loom large. Investment recommendation: "Buy" for high-risk tolerance investors, hinging on upcoming FDA decision on acoramidis and management of significant debt obligations.

BridgeBio: Bets Acoramidis As The Pfizer Spoiler

BridgeBio Pharma Inc.'s stock BBIO, +1.11% jumped 3.8% in premarket trade Monday, after the company announced a $250 million private investment in public equity, or PIPE, equity offering led by the Qatari sovereign fund. The Palo Alto, Calif.

BridgeBio's stock jumps 3.8% premarket after company announces $250 million PIPE financing led by Qatari sovereign fund

- $250 million financing led by Qatar Investment Authority (QIA) with significant participation from four of the largest investment management firms in the US

BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

Alnylam Pharmaceuticals

Roche Holding AG

The pharmaceutical industry is one of the most dynamic and innovative sectors in the world. It is constantly developing new drugs and treatments to address various health challenges and improve the quality of life of millions of people.

Buy List Alert: 3 Pharma Stocks with Positive Trial Updates

PALO ALTO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Tuesday, September 12 at 10:50 am ET.

BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA)

BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

BridgeBio Pharma stands a chance of taking on Pfizer in a heart disease, an analyst said Monday. But BBIO stock reversed its premarket gain.

Pfizer Was First In Treating This Heart Disease. Why BridgeBio Could Be Better.

- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023

PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2023, taking place in Amsterdam, Netherlands on August 25 - 28, 2023. ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR).

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

This young biotech might soon commercialize a new medicine. Analysts see BridgeBio's shares headed upward.

Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?

- Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 (p

BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

- BridgeBio met with the U.S. Food and Drug Administration (FDA) to discuss the use of glycosylated αDG levels as a surrogate endpoint; based on this meeting, the Company believes there is potential to pursue Accelerated Approval in the U.S. for BBP-418

BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study

BridgeBio Pharma focuses on oncology and genetic diseases. The company said that acoramidis fared well in treating a heart muscle disease.

Why Shares of BridgeBio Pharma Skyrocketed This Week

BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.

BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study

BridgeBio Pharma ( BBIO , Financial) is a clinical-stage biopharmaceutical company that focuses on developing transformative medicines for patients with rare diseases. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology and Gene therapy.

BridgeBio Pharma Surges on Positive Heart Drug News

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?

Primary endpoint met in BridgeBio Pharma, Inc.'s phase 3 ATTRibute-CM study, which used acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy; NDA filing expected before end of 2023. Results from the phase 3 ATTRibute-CM study were accepted as a late-breaker presentation for the European Society of Cardiology Congress 2023, taking place August 25 to August 28 of 2023. Results from the phase 3 CALIBRATE study, using encaleret for the treatment of patients with autosomal dominant hypocalcemia type 1 [ADH1] are expected by 1st half of 2024.

BridgeBio Pharma: Positive ATTR-CM Treatment Data Leads To Other 2023 Catalysts

BridgeBio Pharma, Inc. has reported encouraging results from its Phase 3 ATTRibute-CM study of acoramidis, a potential treatment for Transthyretin amyloid cardiomyopathy. The company's financial health is robust, with cash and equivalents increasing to $467.0 million, and operating costs and expenses decreasing to $128.0 million due to cost streamlining and reprioritized R&D programs. If approved, acoramidis could cater to a significant patient population previously untreated with disease-modifying therapy, potentially disrupting the current treatment landscape and competing with Pfizer's tafamidis.

BridgeBio Pharma's Breakthrough Potential In ATTR-CM Treatment Market

BridgeBio Pharma Inc shares surged 69% to $30.78 in late-morning trading on Monday after the commercial-stage biopharmaceutical company announced that Acoramidis, its drug development candidate for a rare heart disease, showed significant improvement in patients in a late-stage study. Acoramidis is being developed to treat transthyretin amyloid cardiomyopathy in which abnormal deposits of a protein called amyloid buildup in the heart, and can cause heart failure, Reuters reported.

BridgeBio Pharma stock soars on heart disease drug study results

BridgeBio Pharma Inc (NASDAQ:BBIO) stock is one of the best stocks on Wall Street today, after the pharma name's heart disease drug, acoramidis, met the main goal in a late-stage study.

Pharma Stock Soars on Heart Disease Drug Trial

Ionis Pharma

BridgeBio landed a "best-case scenario" for its heart-disease drug on Monday, helping BBIO stock and shares of competitors to rocket.

BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease

BridgeBio Pharma (NASDAQ: BBIO ) stock is climbing higher on Monday as investors react to results from a Phase 3 clinical trial. These results come from the company's ATTRibute-CM study of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM).

Why Is BridgeBio (BBIO) Stock Up 63% Today?

BridgeBio Pharma Inc.'s stock BBIO, +5.26% rocketed 66% in premarket trade Monday, after the company announced positive results in a late-stage trial of a treatment for transthyretin amyloid cardiomyopathy, or ATTR-CM, a buildup of faulty proteins on the heart that can cause heart failure. The Palo Alto, Calif.

BridgeBio's stock rockets 66% on news of positive results from late-stage trial of ATTR-CM treatment

BridgeBio Pharma Inc said on Monday its experimental drug to treat a kind of heart disease showed statistically significant improvement in reducing hospitalizations in a late-stage study, sending shares up 64%.

News for BridgeBio Pharma Inc Stock (BBIO)